Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) monotherapy and combination therapy in multiple myeloma
2024-515770-27-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of etentamig in multiple myeloma (MM) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicity (DLT) in Substudy 1, DLT in Substudy 4 and 3 more. Planned start Jan 2026; status: authorised.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515770-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515770-27-00.